Zentalis Pharmaceuticals, Inc.
ZNTL
$2.76
$0.093.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.94% | 0.68% | 44.34% | -1.70% | -18.21% |
| Total Depreciation and Amortization | -1.88% | 0.00% | -38.93% | -17.35% | -1.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 644.85% | 120.96% | -97.55% | -6.21% | 376.36% |
| Change in Net Operating Assets | -17.78% | 85.95% | -574.80% | 124.79% | 2.51% |
| Cash from Operations | -14.75% | 22.31% | -6.35% | 17.80% | 9.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 11,180.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.12% | -5.01% | -26.33% | 25.36% | -33.08% |
| Cash from Investing | 14.58% | -6.77% | -24.95% | 25.38% | -33.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,586.96% | -- | -100.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4,087.83% | -- | -100.00% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -308.89% | 134.02% | -153.94% | 208.21% | -272.94% |